STANDARD BIOTOOLS (LAB) director takes 51,282 RSUs in lieu of $60K cash

Rhea-AI Filing Summary

Carey Thomas D. reported acquisition or exercise transactions in this Form 4 filing.

STANDARD BIOTOOLS INC. director Thomas D. Carey received a grant of 51,282 shares of common stock in the form of restricted stock units valued at $1.17 per share. These RSUs were taken in lieu of $60,000 in cash board compensation and will vest in four equal quarterly installments during 2026, subject to his continued service. Following this grant, his directly held common stock totals 245,340 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carey Thomas D.

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON MA 02109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		51,282(1)	A	$1.17	245,340(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2026, subject to the Reporting Person's continued service through the applicable vesting date.

2. The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $60,000 in cash compensation for certain services as a board member.

	/s/ Thomas D. Carey by Tomone Tanaka, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did STANDARD BIOTOOLS (LAB) report for Thomas D. Carey?

STANDARD BIOTOOLS reported that director Thomas D. Carey received 51,282 restricted stock units of common stock. The award was recorded at $1.17 per share and represents equity compensation in lieu of cash for his board service during 2026.

How many STANDARD BIOTOOLS (LAB) shares does Thomas D. Carey hold after this Form 4?

After the reported grant, Thomas D. Carey directly holds 245,340 shares of STANDARD BIOTOOLS common stock. This total includes the newly awarded 51,282 restricted stock units, which will vest over 2026 subject to his continued service on the company’s board.

What is the structure of the RSU award reported for STANDARD BIOTOOLS (LAB) director Carey?

The award consists of 51,282 restricted stock units that vest 25% on the last day of the last month of each fiscal quarter of 2026. Vesting is conditioned on Thomas D. Carey continuing to serve the company through each scheduled vesting date.

Why did STANDARD BIOTOOLS (LAB) grant RSUs instead of cash to Thomas D. Carey?

Thomas D. Carey elected to receive restricted stock units instead of $60,000 in cash compensation for certain board services. This election converts what would have been cash fees into equity-based compensation, aligning part of his remuneration with the company’s stock performance.

What was the reported value per share of the RSUs granted by STANDARD BIOTOOLS (LAB)?

The RSUs granted to Thomas D. Carey were reported at $1.17 per share. This per-share figure is used to determine the number of units issued in exchange for $60,000 of foregone cash compensation related to his role as a board member.